Regeneron has secured accelerated FDA approval for linvoseltamab, its bispecific antibody targeting multiple myeloma in adults with relapsed or refractory disease. This milestone follows delays and aims to bolster Regeneron’s oncology portfolio alongside other bispecific candidates. The therapy represents a novel immunotherapeutic approach engaging dual antigens to attack malignant plasma cells. Meanwhile, the acquisition trend for struggling biotechs continues, with Concentra Biosciences recently agreeing to acquire IGM Biosciences following pipeline and operational setbacks at the latter.